GlassScriptPhysician profile
Christy L Baker
NPI 1780671651
$18,362.20
in general payments reported to CMS, 2019-2025
28 companies · $3,491 in 2025
The $3,491 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,700 · 2022: $3,708 · 2023: $3,639 · 2024: $5,825 · 2025: $3,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,900 · Education: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,320.12 |
| Consulting Fee | $1,900.00 |
| Education | $734.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,557.93 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $3,113.20 | 2021-2025 | |
| Abbvie INC. | $2,608.56 | 2021-2025 | |
| Janssen Biotech, INC. | $1,148.53 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $992.66 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $985.58 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $753.15 | 2021-2025 | Dupixent |
| Pfizer INC. | $641.30 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $578.55 | 2022-2025 | Siliq, Targretin, Jublia |
| Amgen INC. | $551.26 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $455.22 | 2021-2025 | |
| Galderma Laboratories, L.P. | $448.87 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Sun Pharmaceutical Industries INC. | $368.09 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Leo Pharma INC. | $324.31 | 2021-2025 | Adbry |
| Incyte Corporation | $209.15 | 2021-2025 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.09 | 2023-2024 | Spevigo, Cyltezo |
| Journey Medical Corporation | $101.85 | 2021 | |
| Arcutis Biotherapeutics, INC. | $94.57 | 2024-2025 | Zoryve |
| Botanix Sb INC | $50.77 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $43.48 | 2023-2024 | Vtama |
| Almirall LLC | $42.20 | 2022-2025 | Klisyri |
| Organon LLC | $39.46 | 2023-2025 | Vtama, Hadlima |
| Lnhc, INC | $30.27 | 2025 | Zelsuvmi |
| Sandoz INC. | $23.55 | 2024 | Hyrimoz |
| Teva Pharmaceuticals USA, INC. | $19.40 | 2024 | Simlandi |
| Dermira, INC. | $18.99 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.04 | 2022 | |
| Merz North America, INC. | $15.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.